Table II.
Summary of bevacizumab in reviewed clinical trials.
| Study | Year | Number of patients | Median age (years) | Pre-treat mean Derkay score | Pre-treat surgical rate (surgery per year) | Post-treat mean Derkay score | Post-treat surgical rate (surgery per year) | HPV type | Dose of bevacizumab (mg) | Results and conclusions |
|---|---|---|---|---|---|---|---|---|---|---|
| Albanedo Terrazas et al. 28 | 2022 | 6 | 20 | 9 | 1 | 1.5 | 0 | 25 mg/ml | Decrease of Derkay scores but no statistical significance | |
| 2 Jo | ||||||||||
| 4 Ao | ||||||||||
| Rogers et al. 45 | 2013 | 10 | 8 | 19 | 8 | 13 | 4 | HPV 11 | 2.5 mg/ml (0.5 ml) | Bevacizumab may indeed limit the number of surgical procedures required per year and increase the duration between procedures in patients with aggressive RRP, while simultaneously improving voice outcomes |
| 7 Jo | HPV 6 | |||||||||
| 3 Ao | ||||||||||
| Best et al. 46 | 2012 | 43 | 48 | Higher doses of bevacizumab are relatively safe in adult patients | ||||||
| 43 Ao | ||||||||||
| Zeitels et al. 24 | 2011 | 20 | Range (18-60) | 7.5-12.5 mg | 3 complete responses, 16 partial responses with less disease in treated vocal fold, 1 more disease in the treated vocal fold. Treating RRP by coupling the antiangiogenetic agent bevacizumab with KTP laser photoangiolysis is synergistic |
Jo: Juvenile onset; Ao: Adult onset.